Portico™ Valve, Portico Delivery System(s) and Loading System(s)
DeviceSubjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
NCT Number: NCT03752866
The purpose of this clinical investigation is to characterize the procedural safety and device performance of transfemoral implantation of the Portico™ Transcatheter Aortic Heart Valve in patients with symptomatic degenerative aortic stenosis.
Looking for future studies?
Notify Me18 year–100 year
All sexes
Interventional
Not applicable
Heart Care Partners- Wesley Hospital, Woolloongabba, Queensland, Australia
The CONFIDENCE registry study will be conducting as a prospective, non-randomized, observational, single-arm, multi-center study.
Approximately 1000 subjects with severe symptomatic (NYHA class ≥ II) aortic stenosis (AS), will undergo Portico™ Transcatheter Aortic Heart Valve implantation.
The subject data will be collected at baseline, index procedure, pre- discharge, 30 days and 12 months from the index procedure.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the Portico TAVI system.
Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve using the FlexNav Delivery and Loading Systems.
Time frame: 30 days from the index procedure
Death due to proximate cardiac cause, non-coronary vascular conditions, procedure-related deaths, valve-related deaths, sudden or unwitnessed death and unknown cause.
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
The increase in creatinine must occur within 48 hours.
Stage 1: Increase in serum creatinine to 150% to 199% (1.5 to 1.99 X increase compared with baseline) or increase of greater than or equal to 0.3 mg/dL (26.4 mmol/L) or Urine output <0.5 mL/kg per hour for >6 but <12 hours.
Stage 2: Increase in serum creatinine to 200% to 299% (2.0 to 2.99 X increase compared with baseline) or Urine output <0.5 mL/kg per hour for >12 but <24 hours.
Stage 3: Increase in serum creatinine to greater than or equal to 300% (3 X increase compared with baseline) or serum creatinine of ≥ 4.0 mg/dL (354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L)or Urine output <0.3 mL/kg per hour for ≥24 hours or anuria for ≥12 hours. Patients receiving renal replacement therapy are considered to meet Stage 3 criteria irrespective of other criteria.
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
Time frame: At 30 days
This is a yes or no question on the CRF. Sites report if the implanter used an introducer sheath (a special device used to facilitate introduction of the investigational device into the subjects vasculature).
Time frame: At 30 days
Time frame: At 30 days
Effective orifice area is a measure of the working area of the implanted valve determined by echocardiograph.
Time frame: At 30 days
Aortic valve mean gradient is a measure of the pressure gradient across the aortic valve measured by echocardiograph.
Time frame: At 30 days
Time frame: At 30 days
NYHA Functional Classification is a system used to assess patient heart failure severity based on their limitations of physical activity. The four classes are described below:
Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or shortness of breath.
Class II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain.
Class III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain.
Class IV: Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Subjects' NYHA Classification based on above criteria was assessed during follow up, and subjects were assigned to one of four classifications. Results are presented as percentage of all available subjects who were assigned each functional class (I-IV).
Time frame: At 30 days
The EQ-5D-3L consists of EuroQoL 5 questions and 3 answering levels. The rating of questions includes: Level 1 no problems; Level 2 some problems; Level 3 Significant problems; Worst case is 15 points; and best case is 5 points using index. The Visual analogue scale VAS 0-100 where 0 is the worst imaginable health state and 100 the best imaginable health state."
Time frame: At 12 months
Kaplan-Meier (KM) percentage of subjects who died. KM is a statistical method that attempts to account for other factors that may have reduced the number of subjects evaluable at a given time point.
Abbott Medical Devices
Industry
CONtrolled Delivery For ImproveD outcomEs With cliNiCal Evidence
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01675440
Aortic Valve Disease, Aortic Valve Stenosis
Phoenix, Arizona, United States
View Trial DetailsNCT04206228
Anemia, Anemia, Hypochromic
Oslo, Norway
View Trial DetailsNCT07304427
Aortic Valve Disease, Aortic Valve Stenosis
Zhanjiang, Guangdong, China
View Trial DetailsNCT06834828
Aortic Valve Disease, Aortic Valve Stenosis
Abbasia, Cairo Governorate, Egypt
View Trial Details